Portfolio example: Dr. Reddys

Vertically integrated generics supplier with a global focus

Facts and Figures

Region: Emerging Markets
Subsector: Specialty Pharma/ Generics
Market capitalization: USD 9.2 bn*
Revenue 2022: USD 2.9 bn

Revenue breakdown by product groups and regions

Global Generics	83%
Pharmaceut. Services & API	15%
Proprietary Products & others	2%

North America	47%
India	21%
Russia	12%
Europe	8%
RoW	7%
Other CIS	5%

Investment idea

- Refocus on key markets by new management team paying off
- Promising pipeline in the USA with significant launches in the coming years
- Catching up in India with integration of Wockhardt portfolio and new molecule launches
- Broad COVID-19 portfolio (incl. Remdesivir and Sputnik vaccine)
- Solid balance sheet, high cash flows and double-digit sales growth expected in the coming years

ESG valutation of Sustainalytics

ESG Risk Rating

26.6

Negligible 0-10	Low 10-20	**Medium 20-30**	High 30-40	Severe 40+

UN Global Compact

Compliant	Watchlist	Non-Compliant

Controversy Scale

Low: 1	Moderate: 2	**Significant: 3**	High: 4	Severe: 5

Controversial business areas

Animal testing

Source: Dr. Reddy's, Bellevue Asset Management, Bloomberg, Sustainalytics, *as of May 31, 2023